PHILADELPHIA--(BUSINESS WIRE)--AVAX Technologies, Inc. (other OTC: “AVXT”) today announces it has expanded its ongoing Phase 1/2 study (“Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients with relapsed Stage III or IV Ovarian Cancer”) to include all five Cancer Treatment Centers of America® (CTCA) regional hospitals. In addition, clinical data from the study was selected to be presented at the Society of Gynecologic Oncology (“SGO”) 19th Annual Winter Meeting February 20 – 22, 2014 at Breckenridge, Colorado. The SGO is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers.
Help employers find you! Check out all the jobs and post your resume.
